Loading…
Employees: 209
Size NeuroPace (NPCE) is a United States Health Care company (Medical Specialties) with a market value of $429M, the 2804th largest of 3,117 United States companies the cockpit tracks. Shares closed at $12.50 on 6 Nov 2026.
Performance Over six months the shares fell 31.9%, against -20.2% for the median peer and -1.1% for the United States market (cap-weighted) — 6th lowest of 20 in its peer set.
Growth Revenue grew 11.6% over the last twelve months (peer median +11.2%); the operating margin is -15.3% (peer median 3.6%).
Valuation It trades at 4.5× enterprise value to sales against a peer median of 5.5× (10th cheapest of 21).
Capital Return on invested capital runs 53.0 points below its cost of capital (13.5% WACC).
Backlog Backlog (remaining performance obligations) was $1.60M at 30 Jun 2026, flat on a year earlier — 0.0 years of trailing revenue. Backlog detail →
Short interest Short interest is 2.6% of the free float (15 Oct 2026).
Next results Next results expected around 12 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $98.8M | $100.0M | $79.9M | $65.4M | $45.5M |
| Revenue growth | — | +25% | +22% | +44% | — |
| Gross profit | $78.7M | $77.2M | $59.1M | $48.1M | $32.5M |
| EBITDA | -$13.0M | -$14.4M | -$19.9M | -$25.6M | -$37.8M |
| Net income | -$19.1M | -$21.5M | -$27.1M | -$33.0M | -$47.1M |
| Free cash flow | -$11.6M | -$11.3M | -$18.3M | -$19.9M | -$37.5M |
| Capital expenditure | $369,000 | $332,000 | $306,000 | $173,000 | $603,000 |
| Total debt | $69.9M | $70.8M | $73.3M | $72.4M | $69.8M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | NPCE | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +0.9% | -12.7% | 3rd highest of 21 |
| 6-month return | -31.9% | -20.2% | 6th lowest of 20 |
| Distance from 52-week high | -36.2% | -40.9% | 7th highest of 21 |
| Revenue growth (TTM) | +11.6% | +11.2% | 11th highest of 21 |
| Operating margin | -15.3% | 3.6% | 8th lowest of 21 |
| EV / Sales | 4.5× | 5.5× | 10th cheapest of 21 |
| ROIC minus cost of capital | -53.0 pp | -4.9 pp | 3rd lowest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| NeuroPace NPCE | United States | $429M | -32% | +12% | -15% | 4.5× | n/a | n/a |
| Shoulder Innovations SI | United States | $428M | +56% | +61% | -59% | 5.7× | n/a | n/a |
| Shanghai Titan Scientific 688133.SS | China | $432M | -22% | -5% | -5% | 1.5× | n/a | n/a |
| SS Innovations International SSII | United States | $423M | -45% | +90% | -16% | 8.0× | n/a | n/a |
| YD Bio YDES | United States | $423M | -58% | +17% | -883% | 704.2× | n/a | n/a |
| 908 Devices MASS | United States | $436M | +29% | +1% | -35% | 5.5× | n/a | n/a |
| Guanhao Biotech 300238.SZ | China | $440M | -25% | -7% | 5% | 7.8× | n/a | n/a |
| Shanghai General Healthy Information & Technology 605186.SS | China | $417M | +3% | +12% | 6% | 8.1× | 55.5% | +3.8% |
| Chison Medical Technologies 688358.SS | China | $443M | -16% | -1% | 19% | 4.4× | 11.8% | +5.6% |
| Medcaptain Medical Technology 2041.HK | Hong Kong | $412M | n/a | +19% | 3% | 1.6× | 23.3% | +18.1% |
| SEERS 458870.KS | South Korea | $409M | -70% | +425% | 43% | 5.5× | -9.1% | +247.0% |
| Brainsway Ltd Sponsored ADR BWAY | United States | $450M | -35% | +32% | 12% | 6.5× | 34.3% | +18.8% |
| PROTEINA 468530.KS | South Korea | $450M | -2% | -59% | -1,178% | 410.3× | n/a | n/a |
| Beijing Succeeder Technology 688338.SS | China | $408M | -15% | -4% | 31% | 5.4× | 9.8% | +3.4% |
| Cerus CERS | United States | $408M | -23% | +14% | -12% | 1.9× | n/a | n/a |
| Shanghai Kehua Bio-Engineering 002022.SZ | China | $407M | -14% | +3% | -45% | 1.9× | n/a | n/a |
| Ningbo Tianyi Medical Appliance 301097.SZ | China | $407M | -20% | +46% | 8% | 4.3× | n/a | n/a |
| Guangdong Transtek Medical Electronics 300562.SZ | China | $406M | -13% | +7% | 11% | 2.0× | -2.5% | -6.0% |
| Hunan Sundy Science and Technology 300515.SZ | China | $453M | -13% | +10% | 27% | 3.7× | 0.9% | +15.6% |
| Eiken Chemical 4549.T | Japan | $454M | -29% | +4% | 6% | 1.5× | n/a | n/a |
| Jenscare Scientific 9877.HK | Hong Kong | $463M | -32% | +993% | -106% | 20.2× | n/a | n/a |
NeuroPace reported $1.60M of remaining performance obligations at 30 Jun 2026, flat from a year earlier and down 16% from the previous quarter. That is 0.0 years of trailing revenue already under contract. Book-to-bill last quarter: 0.99.